A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

(2013) David V Gold et al.   Molecular Cancer

Mucins in pancreatic cancer and its microenvironment

(2013) Sukhwinder Kaur et al.   Nature Reviews Gastroenterology & Hepatology

Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score

(2013) Sinziana Dumitra et al.   HPB

Early diagnosis of pancreatic cancer: challenges and new developments

(2012) Sukhwinder Kaur et al.   Biomarkers in Medicine

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma

(2012) David V. Gold et al.   CANCER

Neutrophil Gelatinase-Associated Lipocalin, Macrophage Inhibitory Cytokine 1, and Carbohydrate Antigen 19-9 in Pancreatic Juice

(2012) Sukhwinder Kaur et al.   PANCREAS

Serum Biomarker Panels for the Detection of Pancreatic Cancer

(2011) R. E. Brand et al.   CLINICAL CANCER RESEARCH

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

(2010) S. Bünger et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

(2009) M. J. Duffy et al.   ANNALS OF ONCOLOGY

Biology and management of pancreatic cancer

(2007) P Ghaneh et al.   POSTGRADUATE MEDICAL JOURNAL